These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. Jendralla H; Baader E; Bartmann W; Beck G; Bergmann A; Granzer E; von Kerekjarto B; Kesseler K; Krause R; Schubert W J Med Chem; 1990 Jan; 33(1):61-70. PubMed ID: 2153213 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. Beck G; Kesseler K; Baader E; Bartmann W; Bergmann A; Granzer E; Jendralla H; von Kerekjarto B; Krause R; Paulus E J Med Chem; 1990 Jan; 33(1):52-60. PubMed ID: 2296036 [TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858 [TBL] [Abstract][Full Text] [Related]
6. Biochemical aspect of HMG CoA reductase inhibitors. Endo A; Hasumi K Adv Enzyme Regul; 1989; 28():53-64. PubMed ID: 2696346 [TBL] [Abstract][Full Text] [Related]
7. Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition. Bischoff H; Angerbauer R; Boberg M; Petzinna D; Schmidt D; Steinke W; Thomas G Atherosclerosis; 1998 Sep; 139 Suppl 1():S7-13. PubMed ID: 9811153 [TBL] [Abstract][Full Text] [Related]
8. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Qin W; Infante J; Wang SR; Infante R Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634 [TBL] [Abstract][Full Text] [Related]
10. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500 [TBL] [Abstract][Full Text] [Related]
11. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Alberts AW Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
13. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells. Nagata Y; Hidaka Y; Ishida F; Kamei T Biochem Pharmacol; 1990 Aug; 40(4):843-50. PubMed ID: 2167097 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Slater EE; MacDonald JS Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125 [TBL] [Abstract][Full Text] [Related]
15. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 5. 6-(Fluoren-9-yl)- and 6-(fluoren-9-ylidenyl)-3,5-dihydroxyhexanoic acids and their lactone derivatives. Stokker GE; Alberts AW; Gilfillan JL; Huff JW; Smith RL J Med Chem; 1986 May; 29(5):852-5. PubMed ID: 3701793 [TBL] [Abstract][Full Text] [Related]
16. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Bischoff H; Angerbauer R; Bender J; Bischoff E; Faggiotto A; Petzinna D; Pfitzner J; Porter MC; Schmidt D; Thomas G Atherosclerosis; 1997 Nov; 135(1):119-30. PubMed ID: 9395280 [TBL] [Abstract][Full Text] [Related]
17. HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts. Connolly PJ; Westin CD; Loughney DA; Minor LK J Med Chem; 1993 Nov; 36(23):3674-85. PubMed ID: 8246237 [TBL] [Abstract][Full Text] [Related]
18. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Gerson RJ; MacDonald JS; Alberts AW; Chen J; Yudkovitz JB; Greenspan MD; Rubin LF; Bokelman DL Exp Eye Res; 1990 Jan; 50(1):65-78. PubMed ID: 2307197 [TBL] [Abstract][Full Text] [Related]
19. Pharmacology of competitive inhibitors of HMG-CoA reductase. Corsini A; Maggi FM; Catapano AL Pharmacol Res; 1995 Jan; 31(1):9-27. PubMed ID: 7784310 [No Abstract] [Full Text] [Related]
20. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]